Interaction Checker

Interaksi Ezetimib

Ezetimib (Zetia) memiliki 18 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 12 mayor, 5 moderat, 1 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (12)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinMayor

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (label Ezetimib, Kontraindikasi)

  • Asam fenofibratfibratMayor

    Co-administration of ZETIA with fibrates other than fenofibrate is not recommended [see Adverse Reactions (6.1) ] . (label Ezetimib, Interaksi obat)

  • AtorvastatinstatinMayor

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (label Ezetimib, Kontraindikasi)

  • Ezetimib dan simvastatinstatinMayor

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (label Ezetimib, Kontraindikasi)

  • FenofibratfibratMayor

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (label Ezetimib, Kontraindikasi)

  • FluvastatinstatinMayor

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (label Ezetimib, Kontraindikasi)

  • GemfibrozilfibratMayor

    Co-administration of ZETIA with fibrates other than fenofibrate is not recommended [see Adverse Reactions (6.1) ] . (label Ezetimib, Interaksi obat)

  • LovastatinstatinMayor

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (label Ezetimib, Kontraindikasi)

  • PitavastatinstatinMayor

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (label Ezetimib, Kontraindikasi)

  • PravastatinstatinMayor

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (label Ezetimib, Kontraindikasi)

  • RosuvastatinstatinMayor

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (label Ezetimib, Kontraindikasi)

  • SimvastatinstatinMayor

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (label Ezetimib, Kontraindikasi)

Interaksi moderat (5)

  • Eltrombopagpenghambat OATP1B1Moderat

    Transporters Use caution when concomitantly administering ALVAIZ and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP)… (label Eltrombopag, Interaksi obat)

  • Kolesevelamsekuestran asam empeduModerat

    Bile Acid Sequestrants Clinical Impact: Concomitant cholestyramine administration decreased the mean exposure of total ezetimibe. (label Ezetimib, Interaksi obat)

  • Kolestipolsekuestran asam empeduModerat

    Bile Acid Sequestrants Clinical Impact: Concomitant cholestyramine administration decreased the mean exposure of total ezetimibe. (label Ezetimib, Interaksi obat)

  • Kolestiraminsekuestran asam empeduModerat

    Bile Acid Sequestrants Clinical Impact: Concomitant cholestyramine administration decreased the mean exposure of total ezetimibe. (label Ezetimib, Interaksi obat)

  • SiklosporinimunosupresanModerat

    Table 3: Clinically Important Drug Interactions with ZETIA Cyclosporine Clinical Impact: Concomitant use of ZETIA and cyclosporine increases ezetimibe and cyclosporine concentrations. (label Ezetimib, Interaksi obat)

Penyebutan minor (1)

  • NiasinMinor

    All participants received simvastatin, 40 to 80 mg per day, plus ezetimibe 10 mg per day if needed, to maintain an LDL-C level of 40-80 mg/dL, and were randomized to receive niacin extended-release tablets 1500-2000 mg/day (n=1718) or matching placebo (IR Niacin, 100-150 mg, n=1696). (label Niasin, Peringatan dan perhatian)

Periksa Ezetimib terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.